Longevity Companies

Altos Labs

A $3B+ biotech focused on cellular rejuvenation through partial reprogramming. Among the largest privately funded life-science companies in history.

BioAge Labs

Public biotech using AI-driven analysis of longitudinal human aging cohorts to identify drug targets. Notable disappointment when lead candidate failed in obesity trial in late 2024.

Calico (Calico Life Sciences)

Alphabet's longevity biotech, founded in 2013 with a long-time-horizon basic-research mandate. Cynthia Kenyon serves as VP of Aging Research.

Cambrian Biopharma

Biotech operating-company portfolio targeting hallmarks of aging. Multiple subsidiaries each addressing one mechanism, with shared infrastructure.

Cyclarity Therapeutics (formerly Underdog Pharmaceuticals)

SENS-Research-Foundation-incubated biotech developing cyclodextrin-based drugs to remove toxic 7-ketocholesterol from arteries. Targets atherosclerosis at the molecular damage level.

Elysium Health

Direct-to-consumer supplement company built around NAD+ precursors and other longevity-adjacent compounds, with an explicit clinical-trial publication strategy.

Genuity Science (acquired)

Genomics company that ran one of the larger population-scale studies of Icelandic-derived ancestry; acquired by HealthVerity in 2023. Demonstrated the value of population-scale genomics for aging research.

Hevolution Foundation

Saudi-Arabian-government-backed non-profit launched in 2022 with $1B/year stated funding commitment for healthspan research. Now the largest single funder of geroscience globally.

Insilico Medicine

AI-first drug-discovery company with a number of clinical-stage candidates, including one of the first AI-discovered, AI-designed drugs to reach Phase 2.

insitro

Machine-learning drug-discovery company founded by Daphne Koller (ex-Coursera, Calico VP). Focused on translating multi-modal cellular data into novel disease targets including aging-relevant indications.

Juvenescence

Holding company investing in and operating multiple longevity-focused biotech subsidiaries. Co-founded by Jim Mellon; pipeline spans senolytics, mTOR modulation, NAD+ biology, and AI drug discovery.

Life Biosciences

David-Sinclair-co-founded biotech holding company spawning multiple subsidiaries focused on different aging mechanisms. Best-known recent programme: partial epigenetic reprogramming for ophthalmic indications.

Loyal (Cellular Longevity)

Biotech developing drugs to extend healthspan and lifespan in dogs — explicitly chosen as a first market because of regulatory tractability and the translational bridge to humans.

Methuselah Foundation

Non-profit founded 2000 by David Gobel and Aubrey de Grey to accelerate human-healthspan research. Ran the Methuselah Mouse Prize ('Mprize') for lifespan-extending interventions in mice.

Mitobridge (acquired by Astellas)

Mitochondrial-medicine biotech acquired by Astellas in 2018 for $225M. Developed PPARδ agonists for muscle and metabolic indications. Demonstrates that mitochondrial-targeted drug discovery has matured into mainstream pharma.

NewLimit

Coinbase-founder-backed biotech using machine learning + perturbation screens to discover novel reprogramming factor combinations beyond the canonical OSKM.

Recursion Pharmaceuticals

Public AI-first drug-discovery company using massive-scale cellular imaging and machine learning. Not exclusively a longevity company but several aging-related programmes; representative of the AI-bio investment wave.

Rejuvenate Bio

George-Church-co-founded biotech developing gene therapies for age-related disease — initially in dogs, with translational ambitions in humans.

Resilience Biosciences (Resilience)

National Resilience is a contract development and manufacturing organisation (CDMO) for cell and gene therapies. Critical infrastructure for longevity biotech because most modern programmes require complex biomanufacturing.

resTORbio (Historic)

Novartis spin-out developing low-dose rapamycin analogs for elderly immune-function indications. Stopped after Phase 3 PROTECTOR-1 trial in respiratory infection failed in 2019. Acquired by Adagene 2020.

Retro Biosciences

Biotech focused on cellular reprogramming, autophagy enhancement, and young-plasma factors. Notable for its early-2022 launch backed by Sam Altman with a 10-year, $180M brief.

SENS Research Foundation

Non-profit research foundation founded by Aubrey de Grey to advance the Strategies for Engineered Negligible Senescence (SENS) damage-repair framework. Funded the seed research for several longevity biotechs.

Sirtris Pharmaceuticals (Historic)

Sirtuin-activating-compound (STAC) biotech co-founded by David Sinclair; acquired by GSK for $720M in 2008. Eventually shuttered after STACs failed to produce reproducible clinical effects. A formative cautionary tale in longevity biotech.

Spring Discovery

AI-first biotech using high-throughput cellular imaging and machine learning to identify compounds that reverse cellular signatures of aging. Quiet but well-funded.

Stealth BioTherapeutics

Mitochondrial-medicine biotech developing elamipretide (SS-31), a tetrapeptide that improves mitochondrial cristae function. Multiple Phase 3 indications in cardiomyopathy, primary mitochondrial myopathy, and dry AMD.

Turn Biotechnologies

Biotech using mRNA-based delivery of Yamanaka factors (ERA — Epigenetic Reprogramming of Aging) for tissue-specific rejuvenation.

Unity Biotechnology

The original senolytic biotech, co-founded by Judith Campisi. Pivoted from systemic senolytics to local intravitreal delivery for diabetic macular edema and AMD.